"Dexcom's Stelo: First FDA-Cleared OTC Continuous Glucose Monitor"
TL;DR Summary
Dexcom has received FDA clearance for its over-the-counter continuous glucose monitor, Stelo, designed for Type 2 diabetes patients who do not use insulin. This marks the first glucose biosensor not requiring a prescription, making it accessible to those without insurance coverage for CGMs. The device, to be available online this summer, offers real-time glucose tracking and lasts up to 15 days. Dexcom aims to provide a simpler experience tailored for Type 2 patients and plans to eventually secure insurance coverage for Stelo.
- Dexcom announces its first-ever over-the-counter CGM Stelo has been cleared by the FDA CNBC
- FDA Approves First OTC Continuous Glucose Monitor Medscape
- FDA Clears Dexcom Stelo Sensor, First OTC Glucose Sensor in Agency History MD Magazine
- Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter Business Wire
- FDA signs off on first over-the-counter continuous glucose monitor UPI News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 3 min read
Condensed
85%
535 → 82 words
Want the full story? Read the original article
Read on CNBC